NO913518L - Vaksiner for ikke typebestembar haemophilus influenzae. - Google Patents

Vaksiner for ikke typebestembar haemophilus influenzae.

Info

Publication number
NO913518L
NO913518L NO91913518A NO913518A NO913518L NO 913518 L NO913518 L NO 913518L NO 91913518 A NO91913518 A NO 91913518A NO 913518 A NO913518 A NO 913518A NO 913518 L NO913518 L NO 913518L
Authority
NO
Norway
Prior art keywords
influenzae
type
protein
testable
vaccines
Prior art date
Application number
NO91913518A
Other languages
English (en)
Other versions
NO913518D0 (no
Inventor
Bruce A Green
Gary W Zlotnick
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Publication of NO913518D0 publication Critical patent/NO913518D0/no
Publication of NO913518L publication Critical patent/NO913518L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Protein "e" fra H. influenzae, et lipoprotein på ca. 28 000 i dalton, er blitt renset og sekvensbestemt. Protein "e" og peptider eller proteiner som har en felles epitop, kan anvendes til vaksinasjon mot ikke typebestembar (og typebestembar) H. influenzae og for forhindring av mellomørebetennelse forårsaket j av H. influenzae. For dette formål kan protein "e" eller | derivater derav fremstilles i naturlig, syntetisk eller rekombinant form og kan administreres alene eller sammen med - andre antigener av H. influenzae. Protein "e" kan også anvendes i multivalente vaksiner utformet for H. influenzae og en eller flere andre infeksiøse organismer.
NO91913518A 1989-03-09 1991-09-06 Vaksiner for ikke typebestembar haemophilus influenzae. NO913518L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09
PCT/US1990/001317 WO1990010458A1 (en) 1989-03-09 1990-03-09 Vaccines for nontypable haemophilus influenzae

Publications (2)

Publication Number Publication Date
NO913518D0 NO913518D0 (no) 1991-09-06
NO913518L true NO913518L (no) 1991-10-29

Family

ID=23248627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91913518A NO913518L (no) 1989-03-09 1991-09-06 Vaksiner for ikke typebestembar haemophilus influenzae.

Country Status (13)

Country Link
US (4) US5601831A (no)
EP (2) EP0606921B1 (no)
JP (1) JP2955014B2 (no)
KR (1) KR100188323B1 (no)
AT (2) ATE110965T1 (no)
AU (1) AU648251B2 (no)
CA (1) CA2047681C (no)
DE (2) DE69012318T2 (no)
DK (2) DK0606921T3 (no)
ES (2) ES2063965T3 (no)
FI (1) FI914241A0 (no)
NO (1) NO913518L (no)
WO (1) WO1990010458A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
EP0624376B1 (en) * 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
KR19990007858A (ko) * 1995-04-17 1999-01-25 존 더블유.로우 박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
WO2002089839A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
JP3704471B2 (ja) * 1997-11-12 2005-10-12 エフ．ホフマン−ラ ロシュ アーゲー レチノイド拮抗薬を用いるヘルパーｔ細胞媒介性免疫疾患の処置
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
DK1189935T3 (da) * 1999-06-25 2009-02-09 Wyeth Corp Ekstraktion af integrale membranproteiner
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
AU6786600A (en) * 1999-08-20 2001-03-19 General Hospital Corporation, The Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫***指导的疫苗
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
WO2002100891A2 (en) * 2001-06-12 2002-12-19 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP2005532789A (ja) * 2002-03-15 2005-11-04 ワイス・ホールデイングス・コーポレーシヨン 減少した酵素活性を有する型別不能なインフルエンザ菌（Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａ）のＰ４タンパク質の変異体
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
PT1915913E (pt) * 2006-10-23 2016-02-16 Nestec Sa Modulação do sabor e do aroma de produtos lácteos por biotransformação
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2010204066B2 (en) * 2009-01-07 2015-03-19 Otsuka Pharmaceutical Co., Ltd. Method for detecting all Haemophilus influenzae
ES2850973T3 (es) 2010-08-23 2021-09-01 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
CN110234658B (zh) 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
JPS62502262A (ja) * 1985-03-27 1987-09-03 ブロンコスタット・プロプライアタリー・リミテツド アジユバントを含有しないワクチン
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
EP0462210B1 (en) 1994-09-07
FI914241A0 (fi) 1991-09-09
DE69033600T2 (de) 2001-04-05
JPH07508972A (ja) 1995-10-05
DK0606921T3 (da) 2000-09-04
EP0606921B1 (en) 2000-08-02
EP0606921A1 (en) 1994-07-20
DE69012318D1 (de) 1994-10-13
CA2047681A1 (en) 1990-09-10
ATE195076T1 (de) 2000-08-15
AU5332690A (en) 1990-10-09
AU648251B2 (en) 1994-04-21
US6420134B1 (en) 2002-07-16
WO1990010458A1 (en) 1990-09-20
US5955580A (en) 1999-09-21
ES2150450T3 (es) 2000-12-01
CA2047681C (en) 2000-02-01
JP2955014B2 (ja) 1999-10-04
EP0462210A1 (en) 1991-12-27
ES2063965T3 (es) 1995-01-16
US5601831A (en) 1997-02-11
DE69012318T2 (de) 1995-03-09
NO913518D0 (no) 1991-09-06
DE69033600D1 (de) 2000-09-07
KR100188323B1 (ko) 1999-06-01
US5780601A (en) 1998-07-14
DK0462210T3 (da) 1994-10-10
ATE110965T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
NO20002413D0 (no) Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer
RU98101249A (ru) Омр26 антиген haemophylus influenzae
ES2180758T3 (es) Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
CA2014033A1 (en) Compositions and treatments for pneumonia in animals
EA199800208A1 (ru) Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы
DK0469045T3 (da) Syntetiske Pseudomonas aeruginosa pilinpeptider og beslægtede vacciner diagnostica
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
DE69434000T2 (de) Impfstoffzusammensetzungen
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
GB2314560A (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
WO2000018429A3 (en) Vaccine based on attenuated $i(haemophilus somnus)
CA2007248A1 (en) Meningococcal class 1 outer-membrane protein vaccine